You are here
SCALABLE NANO PARTICLE PRODUCTION OF LOW BIOAVAILABILITY PHARMACEUTICALS FOR AUGMENTED AQUEOUS SOLUBILITY
- Date Issued:
- 2014
- Abstract/Description:
- The billion dollar pharmaceutical research and development pipeline suffers greatly from high attrition rates of novel therapeutic compounds within pre-clinical and clinical trials. Poor bioavailability in many new drugs, originating in the various methodologies of high throughput screening, may explain part of these growing failure rates. One interpretation of this phenomenon relies on bioavailability's correlation with aqueous solubility; much modern processing allows chemicals to fully develop without touching water, yielding upwards of 90% of new chemical entities practically insoluble in aqueous media. Thus, one approach to alleviating bioavailability and potentially clinical attrition rates necessitates augmented aqueous solubility. The amorphous nanoparticle presents the largest boost in aqueous solubility of a chemical through processing alone. In this contribution, we propose electrospray as a novel, competitive candidate to produce pharmaceutical amorphous nanoparticles with the intent of augmenting solubility. Electrospray represents an idyllic nominee for three reasons: repeatability, flexibility, and scalability. Electrospray offers low batch to batch variation with less than 30% relative standard deviation between various droplets. This triumphs over the several orders of magnitude in variation in pneumatic sprays. Electrospray's flexibility draws from its ability to attain diameters over several orders of magnitude, ranging from hundreds of microns to several nanometers; in this contribution droplets are produced between 500 nm and 1 [micro]m. Finally, electrospray displays scalability to any industrial requirement; though a single nozzle operates at mere microliters per hour, a single multiplexed array of emitters may increase this throughput by several orders of magnitude. This exploration, utilizing Indomethacin as a model low solubility chemical, verifies electrospray as a compatible processing tool for the pharmaceutical industry. Scanning electron microscopy coupled with the image analysis software ImageJ gleans the size and shape of emitted (and dried) particles. Amorphicity verification of particles employs grazing angle x-ray diffraction. Finally, ultraviolet and visual spectrum spectroscopy evaluates the solubility advantage of particles.
| Title: | SCALABLE NANO PARTICLE PRODUCTION OF LOW BIOAVAILABILITY PHARMACEUTICALS FOR AUGMENTED AQUEOUS SOLUBILITY. |
|
|---|---|---|
| Name(s): |
Madden, Aaron, Author Deng, Wei Wei, Committee Chair University of Central Florida, Degree Grantor |
|
| Type of Resource: | text | |
| Date Issued: | 2014 | |
| Publisher: | University of Central Florida | |
| Language(s): | English | |
| Abstract/Description: | The billion dollar pharmaceutical research and development pipeline suffers greatly from high attrition rates of novel therapeutic compounds within pre-clinical and clinical trials. Poor bioavailability in many new drugs, originating in the various methodologies of high throughput screening, may explain part of these growing failure rates. One interpretation of this phenomenon relies on bioavailability's correlation with aqueous solubility; much modern processing allows chemicals to fully develop without touching water, yielding upwards of 90% of new chemical entities practically insoluble in aqueous media. Thus, one approach to alleviating bioavailability and potentially clinical attrition rates necessitates augmented aqueous solubility. The amorphous nanoparticle presents the largest boost in aqueous solubility of a chemical through processing alone. In this contribution, we propose electrospray as a novel, competitive candidate to produce pharmaceutical amorphous nanoparticles with the intent of augmenting solubility. Electrospray represents an idyllic nominee for three reasons: repeatability, flexibility, and scalability. Electrospray offers low batch to batch variation with less than 30% relative standard deviation between various droplets. This triumphs over the several orders of magnitude in variation in pneumatic sprays. Electrospray's flexibility draws from its ability to attain diameters over several orders of magnitude, ranging from hundreds of microns to several nanometers; in this contribution droplets are produced between 500 nm and 1 [micro]m. Finally, electrospray displays scalability to any industrial requirement; though a single nozzle operates at mere microliters per hour, a single multiplexed array of emitters may increase this throughput by several orders of magnitude. This exploration, utilizing Indomethacin as a model low solubility chemical, verifies electrospray as a compatible processing tool for the pharmaceutical industry. Scanning electron microscopy coupled with the image analysis software ImageJ gleans the size and shape of emitted (and dried) particles. Amorphicity verification of particles employs grazing angle x-ray diffraction. Finally, ultraviolet and visual spectrum spectroscopy evaluates the solubility advantage of particles. | |
| Identifier: | CFH0004546 (IID), ucf:45179 (fedora) | |
| Note(s): |
2014-05-01 B.S.M.E. Engineering and Computer Science, Dept. of Mechanical, Materials and Aerospace Engineering Bachelors This record was generated from author submitted information. |
|
| Subject(s): |
electrospray nanoparticle monodisperse amorphous solubility |
|
| Persistent Link to This Record: | http://purl.flvc.org/ucf/fd/CFH0004546 | |
| Restrictions on Access: | campus 2017-04-01 | |
| Host Institution: | UCF |

